Coffee Talk: Charting New Pathways With HER2 and TROP2 Therapies – From Early to Advanced Breast Cancer

Highlights from the PER® CME activity "Coffee Talk: Charting New Pathways With HER2 and TROP2 Therapies – From Early to Advanced Breast Cancer" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.

In this podcast, experts Hope S. Rugo, MD, FASCO; Giuseppe Curigliano, MD, PhD; Paolo Tarantino, MD, PhD; and Alastair Thompson, MD, MBChB, BSc (Hons), FRCS (Ed), FACS; discuss and debate recently published results of pivotal clinical trials in early-stage, HER2-positive breast cancer and their implications for patient care.

Earn CME credit by completing the full accredited activity (available through April 7, 2027):
https://www.gotoper.com/mbcc26coffeetalk-activity

This podcast, including the narration, was developed by PER® (Physicians’ Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.

This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.